Clinical Trials Logo

Filter by:
NCT ID: NCT02849782 Completed - Multiple Sclerosis Clinical Trials

Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine.

FAMPISEP
Start date: February 4, 2014
Phase: Phase 4
Study type: Interventional

This prospective monocentric open label trial was realized in the Laboratory of Clinical Functional Exploration of Movement at the University Hospital of Besancon. Cognitive evaluations: 7 days before fampridine treatment initiation (Pre 1), on the day of fampridine treatment initiation (Pre 2), 14 and 21 days after fampridine treatment initiation, respectively Post 1 and Post 2. Gait evaluations were assessed at Pre 1, Pre 2 and Post 1. Fampridine was prescribed according to guidelines issued by the French Health Products Safety Agency at the dose of 10 mg twice daily. Fampridine is indicated for the improvement of walking in MS patients with a walking disability (EDSS 4-6.5). A walking test is recommended to evaluate improvement after 2 weeks of treatment. According to the practitioner evaluation between Pre 2 and Post 1 (i.e. before and after fampridine treatment), patients were classified into 2 groups: responders whose clinical status was improved and non-responders whose clinical status was not improved.

NCT ID: NCT02849756 Completed - Clinical trials for Intensive Care Unit Syndrome

Future of the Older Patients After Intensive Care Unit

DAAR
Start date: February 2015
Phase:
Study type: Observational

Estimate the future six months after the admission in an intensive care unit of the patients of 85 and more years old in terms of autonomy.

NCT ID: NCT02849626 Completed - Clinical trials for Partial-Onset or Primary Generalized Tonic-Clonic Seizures

Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

Start date: November 16, 2016
Phase: Phase 3
Study type: Interventional

This is an open-label, multicenter study with an Extension Phase to evaluate the safety and tolerability of perampanel oral suspension when administered as an adjunctive therapy in children (ages 4 to less than [<] 12 years) with inadequately controlled partial onset seizures (POS) or primary generalized tonic clonic (PGTC) seizures.

NCT ID: NCT02849574 Completed - Addictions Clinical Trials

Evaluation of Changes in Consumption of Drugs and Substances After Incarceration

COSMOS
Start date: January 2015
Phase: N/A
Study type: Observational

To improve the management and risk reduction, it is essential to understand the evolution of the consumption of psychoactive substances, medicated or not in detention; it does not have at present no data on this subject. This work has as main objective to evaluate the development of substance use terms (goods and consumption practices) by the inmates between the period preceding their incarceration and their fifth month in detention.

NCT ID: NCT02849561 Completed - Clinical trials for Cardio Respiratory Arrest

Evaluation of Prognosis Factors of Neurological Evolution in Cardiac Arrest

ACR
Start date: January 2014
Phase: N/A
Study type: Interventional

With the repercussion of 55 cases eachyear for 100 000 inhabitants in France, cardio respiratory arrest is a public health issue. The goal of this study is to evaluate the pupillary light reflex measured by the dimension of the pupil (diameter) as a prognosis factor neurological evolution in post cardiac arrest. By participating to this study, the patient get the same tratments and exams than in a usual managing cares. In addition of these events, the pupillary light reflex is studied as soon as the patient is accepted in the department, and then on the second day. Currently, the evaluation of the neurological becoming rely on a multimodal clinical and paraclinical approach. The study of the pupillary light reflex measured by the diameter of the pupil could be a prognosis factor of neurological evolution for patients in post cardiac arrest, so a reliable and available prognosis marker in patient care. The goal of this study is to evaluate the pupillary light reflex (RPM), measured by the diameter of the pupil as a prognosis factor of neurological evaluation of admitted patients after a cardiac arrest. Principal criteria of judgement is the percentage of the pupillary light reflex variation measured with Neurolight®, compared between two groups.

NCT ID: NCT02849236 Completed - Pain, Postoperative Clinical Trials

PECS I Block for Breast Subpectoral Implant Surgery

Start date: October 16, 2016
Phase: N/A
Study type: Interventional

Breast augmentation surgery can cause important postoperative pain, especially when bilateral subpectoral implants are used. The investigators hypothesized that a technique of regional analgesia, the pectoral nerve block type I (or "PECS I block") would reduce pain within the first twenty-four hours and, in turn, morphine consumption and associated side effects. This is a randomized, controlled, double-blind study which compares intra and postoperative analgesia with or without PECS I block in breast surgery.

NCT ID: NCT02849158 Completed - Clinical trials for Rectum Adenocarcinoma

Fibroblast Before and After Neoadjuvant Chemo-radiotherapy in Patient With Locally Advanced Rectal Adenocarcinoma

FibroRect
Start date: June 9, 2017
Phase: N/A
Study type: Interventional

Single center interventional study to explore activity of fibroblasts in the tumor and away in the healthy rectal tissue.

NCT ID: NCT02849145 Completed - Uveal Melanoma Clinical Trials

Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)

Start date: September 2014
Phase: N/A
Study type: Interventional

Prospective, open labelled, monocentric trial to evaluation of the circulating tumor DNA rate in the blood, before and after curative resection of hepatic metastasis of uveal melanoma (HMUM) and during post-surgery follow-up

NCT ID: NCT02849106 Completed - Colorectal Cancer Clinical Trials

Predictive Response to Chemotherapy (FOLFOX or FOLFIRI) by ex Vivo Culture 3D Technique in Metastatic Colorectal Cancer

CULTURE3D
Start date: May 2011
Phase: N/A
Study type: Interventional

Prospective, open labelled, multicenter trial to evaluate the feasibility of ex vivo culture 3D (chemogram obtaining) on biopsies in order to estimate the predictive value of this technique for treatment response in patients treated by two different chemotherapies (FOLFOX or FOLFIRI) for colorectal cancer.

NCT ID: NCT02848976 Completed - Multiple Sclerosis Clinical Trials

Re-training to Effort (RE) According to the Severity of Multiple Sclerosis: Preliminary Assessments Based on Fatigue and Quality of Life

RE-SEP
Start date: January 2009
Phase: N/A
Study type: Observational [Patient Registry]

Regular physical activity promotes physical and mental well-being in the general population. Patients with multiple sclerosis (MS patients) tend them, to limit their physical activity or because of deficiencies related to the disease, or even on the advice of their caregivers in order to save their functional abilities. Time for leisure activity could be almost 20% lower in MS patients compared to healthy controls, and this situation is likely to aggravate the functional symptoms of multiple sclerosis. The literature described the benefit of physical activity for MS patients according to protocols and varied assessments. Evaluations were indeed concern very analytical elements of metabolic functioning, nervous, muscular, cardiopulmonary etc ... or take into account the performance of components or fatigue and quality of life. Due to the multiplicity of RE protocols, sometimes on the verge of pragmatic goals of functional rehabilitation, the double issue was the profit earned by an RE program and of this benefit by level of severity of MS. The main objective of our study was an evaluation of the effects on fatigue and quality of life of a retraining program to effort suitable for levels of impairment and patients with MS activity limitations. The secondary objective was checking a performance improvement of the patients in this adapted program.